. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Res Social Adm Pharm. 2018 Oct 17;15(8):1007–1013. doi: 10.1016/j.sapharm.2018.10.023

Table 3.

Prescribed opioid dose and prevalence of opioid and benzodiazepine overlap among those with an active opioid prescription on the date of death among a national sample of Veterans who died from prescription opioid overdose, 2012–2013.

	Overall Cohort^a (n= 632)		Dual Enrollees^a (n =154)

	VA-only data	VA and Part D data	VA-only data	VA and Part D data
Daily MME on the date of death, median (Q1, Q3)	40 (0,112)	80 (33,180)	0 (0, 60)	124 (45,285)
Opioid and benzodiazepine overlap on date of death, n(%)	202 (32.0)	263 (41.6)	34 (22.1)	68 (44.2)

AbbreviationsMME = morphine milligram equivalent, SD = standard deviation, Q1 = first quartile, Q3 = third quartile.

Includes 632 of 643 (98%) in overall sample, and 154 of 157 (98%) of dual enrollees after excluding Veterans whose opioid dosage could not be quantified in morphine milligram equivalents (i.e., Veterans only on liquid formulations or suboxone were not counted in these calculations).